-
公开(公告)号：US12060420B2
公开(公告)日：2024-08-13
申请号：US17205251
申请日：2021-03-18
IPC分类号： C07K16/28 , A61K39/00 , A61K39/12 , A61K39/275 , A61K39/395 , C07K16/30 , C07K16/32
CPC分类号： C07K16/2803 , A61K39/12 , A61K39/275 , A61K39/395 , A61K39/3955 , C07K16/2863 , C07K16/2887 , C07K16/2893 , C07K16/30 , C07K16/32 , A61K2039/507 , A61K2039/57 , A61K2039/572 , C07K2317/21 , C07K2317/24 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C12N2710/24034 , C12N2710/24134
摘要： The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g. cancer cells or virus-infected cells, by the host's immune system. Provided is a composition comprising (i) a therapeutic compound that can trigger a host's immune effector cells against an aberrant cell, such as a therapeutic antibody, and (ii) at least one agent capable of reducing or preventing inhibitory signal transduction initiated via SIRPalpha.
-
2.发明公开公开(公告)号：US20240091338A1
公开(公告)日：2024-03-21
申请号：US18115556
申请日：2023-02-28
IPC分类号： A61K39/155 , A61K39/12 , A61K39/235 , A61K39/275
CPC分类号： A61K39/155 , A61K39/12 , A61K39/235 , A61K39/275 , A61K2039/545
摘要： The present invention relates to administration regimens which are particularly suited for vaccine composition comprising polynucleotides which encode immunogenic polypeptides. Said administration regimens involve the repeated administration of a vaccine composition and enhance the immune response against the immunogenic polypeptide.
-
公开(公告)号：US11890270B2
公开(公告)日：2024-02-06
申请号：US17136674
申请日：2020-12-29
发明人： Shanthakumar R. Tyavanagimatt , Melialani A. C. L. S. Anderson , William C. Weimers , Dylan Nelson , Tove' C. Bolken , Dennis E. Hruby , Michael H. O'Neill , Gary Sweetapple , Kelley A. McCloughan
IPC分类号： A61K31/404 , A61K39/275 , C07D209/76 , A61K9/16 , A61K9/48 , C07D209/70
CPC分类号： A61K31/404 , A61K9/1652 , A61K9/4866 , A61K39/275 , C07D209/70 , C07D209/76
摘要： Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.
-
公开(公告)号：US11844832B2
公开(公告)日：2023-12-19
申请号：US16994500
申请日：2020-08-14
发明人： Ian J. Amanna , Elizabeth A. Poore
IPC分类号： A61K39/12 , C12N7/00 , A61P31/14 , A61K39/145 , A61K39/02 , A61K33/40 , A61P31/16 , A61K39/112 , A61K39/275 , A61K39/00
CPC分类号： A61K39/145 , A61K33/40 , A61K39/02 , A61K39/0283 , A61K39/105 , A61K39/12 , A61K39/275 , A61P31/14 , A61P31/16 , C12N7/00 , A61K2039/521 , A61K2039/5252 , C12N2760/16131 , C12N2760/16134 , C12N2760/16163 , C12N2760/16171 , C12N2770/24134 , C12N2770/24163 , C12N2770/24171 , C12N2770/36134 , C12N2770/36163 , C12N2770/36171 , Y02A50/30
摘要： Provided are methods for rapidly inactivating a pathogen, or for producing a vaccine composition containing an inactivated noninfectious pathogen having retained antigenicity and/or immunogenicity, comprising exposing the pathogen to a chemical inactivating agent (e.g., one or more chemical oxidizing, alkylating or crosslinking agents) in the presence of inorganic polyatomic oxyanions in an amount and for a time sufficient to render the pathogen noninfectious while enhancing retention of pathogen antigenicity and/or immunogenicity relative to that retained by contacting the pathogen with the chemical inactivating agent alone. The methods are broadly applicable to pathogens having RNA or DNA genomes (e.g., including viruses, bacteria, fungi, and parasites). Also provided are vaccine compositions (medicaments) containing a pathogen inactivated by exposure to an inactivating agent in the presence of elevated concentrations of inorganic polyatomic oxyanions, and methods for eliciting an immune response in a subject by administering the vaccine compositions.
-
公开(公告)号：US20230338516A1
公开(公告)日：2023-10-26
申请号：US18005291
申请日：2021-08-16
发明人： Melanie MUELLER , Ralf AMANN
IPC分类号： A61K39/275 , C12N15/86 , C07K14/705
CPC分类号： A61K39/275 , C07K14/70532 , C07K14/70575 , C12N15/86 , A61K2039/5256
摘要： The present invention relates to a recombinant Poxviridae vector expressing a co-stimulatory molecule, a cell containing the recombinant Poxviridae vector, a pharmaceutical composition containing the recombinant Poxviridae vector according to the invention and/or the cell according to the invention, and a method for the treatment of a living being in need of a vaccination with an antigen.
-
公开(公告)号：US20230009041A1
公开(公告)日：2023-01-12
申请号：US17732141
申请日：2022-04-28
申请人： Arizona Board of Regents, a body corporate of the State of Arizona acting for and on behalf of , Consejo Superior De Investigaciones Cientificas , IPPOX Foundation
发明人： Giuseppe Pantaleo , Thierry Calandra , Alexandre Harari , Thierry Roger , Mariano Esteban , Bertram Jacobs , Karen Kibler , Cornelius Melief , Rafick-Pierre Sekaly , Elias Haddad , James Tartaglia
IPC分类号： C12N15/86 , A61K39/275 , A61K39/295
摘要： The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.
-
公开(公告)号：US20230002741A1
公开(公告)日：2023-01-05
申请号：US17827320
申请日：2022-05-27
发明人： David Evans , Ryan Noyce , Seth Lederman
IPC分类号： C12N7/00 , A61K39/275 , A61K39/12 , A61P31/20
摘要： The invention relates, in general, to synthetic chimeric poxviruses, compositions comprising such viruses, and the development and use of systems and methods for producing such synthetic chimeric poxviruses. The synthetic chimeric poxviruses are well suited for live virus vaccines and pharmaceutical formulations.
-
公开(公告)号：US20220241421A1
公开(公告)日：2022-08-04
申请号：US17580896
申请日：2022-01-21
IPC分类号： A61K47/26 , A61K9/46 , A61K39/12 , A61K9/20 , A61K39/00 , A61K39/255 , A61K39/275 , A61K9/00 , A61K39/17 , A61K39/215
摘要： The present invention relates to novel stable compressed vaccine composition comprising at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.
-
公开(公告)号：US11345928B2
公开(公告)日：2022-05-31
申请号：US16513757
申请日：2019-07-17
发明人： Giuseppe Pantaleo , Thierry Calandra , Alexandre Harari , Thierry Roger , Mariano Esteban , Bertram Jacobs , Karen Kibler , Cornelius Melief , Rafick-Pierre Sekaly , Elias El Haddad , James Tartaglia
IPC分类号： C12N15/86 , A61K39/12 , A61K39/275 , A61K39/295 , A61K49/00 , A61K39/00
摘要： The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.
-
公开(公告)号：US20210324014A1
公开(公告)日：2021-10-21
申请号：US17357624
申请日：2021-06-24
发明人： Douglas Grant McFADDEN , Mohammed Masmudur RAHMAN , Nancy VILLA , Lino TORRES-DOMINGUEZ , Lina FRANCO ACHURY , Leslie Lynne SHARP
IPC分类号： C07K14/005 , C07K14/525 , C07K14/54 , A61P35/04 , A61K45/06 , A61K39/275 , C12N7/00
摘要： Disclosed herein, in certain embodiments, are recombinant myxoma viruses (MYXVs) and nucleic acid constructs encoding the recombinant MYXVs. In some embodiments, the MYXVs are engineered to inactivate or attenuate an activity or expression level of an M153 protein. In some embodiments, the MYXVs are engineered to express one or more transgenes such as a tumor necrosis factor (TNF), interleukin-12 (IL-12), or decorin. Also disclosed herein, in certain embodiments, are methods of using the MYXVs. Some embodiments include providing a MYXV as described herein to a subject in need thereof.
-
-
-
-
-
-
-
-
-
搜索结果
425 条记录 (耗时 0.033 秒)
